Vaginal disorder
disease diseaseOn this page
Also known as disease of vaginadisease or disorder of vaginadisorder of vaginavagina diseasevagina disease or disordervaginal disease
Summary
Vaginal disorder (MONDO:0001433) is a disease (an umbrella term covering 6 Mondo subtypes) and 27 clinical trials. Top therapeutic interventions include ospemifene, dequalinium, and desflurane. A subtype of female reproductive system disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Umbrella term: 6 Mondo subtypes
- Clinical trials: 27
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | vaginal disorder |
| Mondo ID | MONDO:0001433 |
| MeSH | D014623 |
| DOID | DOID:121 |
| NCIT | C26910 |
| SNOMED CT | 25658005 |
| UMLS | C0042251 |
| MedGen | 12042 |
| Anatomy (UBERON) | UBERON:0000996 |
| Is cancer (heuristic) | no |
Also known as: disease of vagina · disease or disorder of vagina · disorder of vagina · vagina disease · vagina disease or disorder · vaginal disease · vaginal disorder
Disease family
This is a subtype of female reproductive system disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › reproductive system disorder › female reproductive system disorder › vaginal disorder
Related subtypes (33): ectopic pregnancy, pelvic inflammatory disease, endosalpingiosis, prolapse of female genital organ, Allen-Masters syndrome, fallopian tube disorder, vulvar disease, uterine disorder, gynatresia, Bartholin duct cyst, ovarian disorder, hymen, imperforate, preterm premature rupture of the membranes, mammary-digital-nail syndrome, Asherman syndrome, uterine cervical aplasia and agenesis, longitudinal vaginal septum, transverse vaginal septum, polycystic ovaries-urethral sphincter dysfunction syndrome, granulomatous mastitis, vaginal atresia, mullerian aplasia, vulvovaginal gingival syndrome, isolated partial vaginal agenesis, female infertility, female reproductive system neoplasm, polyp of vulva, vulval varices, vulvodynia, menstrual cycle-dependent periodic fever, Bartholin’s gland disease, delayed puberty, self-limited, menstrual disorder
Subtypes (6): vaginitis, vaginal discharge, leukoplakia of vagina, vaginal neoplasm, polyp of vagina, vaginismus
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 27.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 18 |
| PHASE3 | 5 |
| PHASE4 | 2 |
| PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01310582 | PHASE4 | COMPLETED | Recovery Following Desflurane Versus Sevoflurane for Outpatient Urologic Surgery in Elderly Females |
| NCT05788991 | PHASE4 | TERMINATED | Comparison of Dequalinium Chloride (Fluomizin) vs Oral Metronidazole for the Treatment of Bacterial Vaginosis |
| NCT00276094 | PHASE3 | COMPLETED | A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women |
| NCT00566982 | PHASE3 | COMPLETED | A Clinical Study to Evaluate the Safety of Ospemifene |
| NCT00729469 | PHASE3 | COMPLETED | Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity |
| NCT01585558 | PHASE3 | COMPLETED | Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus |
| NCT01586364 | PHASE3 | COMPLETED | Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus |
| NCT00630539 | PHASE2 | COMPLETED | A Clinical Study to Evaluate the Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women |
| NCT05587283 | PHASE1 | UNKNOWN | Safety, Tolerability, and Acceptability Study of Intravaginal Administration of LABTHERA-001 Capsules in Healthy Women |
| NCT05938192 | Not specified | RECRUITING | Multimodality Treatments of HPV-related Lesions of the Female Genital Tract |
| NCT07607470 | Not specified | NOT_YET_RECRUITING | Large Algorithm Setting and Validation Study |
| NCT00890487 | Not specified | UNKNOWN | Hyaluronic Acid and Vaginal Distress |
| NCT02534779 | Not specified | COMPLETED | Assessing the Disintegration, Safety, and Acceptability of Placebo Vaginal Inserts for the Delivery of Vaginal Products |
| NCT03940612 | Not specified | COMPLETED | Probiotic for Vaginal Candidiasis in Pregnant Women |
| NCT04245293 | Not specified | COMPLETED | Clinical Trial Study To Evaluate The Performance And Safety Of Ainara® |
| NCT04245358 | Not specified | COMPLETED | Open Non-Comparative Clinical Trial Study To Evaluate The Performance And Safety Of Ainara® |
| NCT04247022 | Not specified | COMPLETED | Evaluation of Gynecological Acceptability of a Health Care Product |
| NCT04327947 | Not specified | COMPLETED | Evaluation of Gynecological Acceptability of 3 Health Care Products |
| NCT04362371 | Not specified | COMPLETED | Post Marketing Follow Up Study To Evaluate Performance Safety Quality of Menopausal Transition Women Treated With Ainara |
| NCT04664985 | Not specified | UNKNOWN | Evaluation of Mucogyne® Ovule in Vulvovaginal Dryness Management in Women Treated by Brachytherapy and/or Radiotherapy for Endometrial or Cervical Cancer. |
| NCT04887636 | Not specified | COMPLETED | Baseline Study of Vaginal Microbiota in Healthy Chinses Female Population |
| NCT05709119 | Not specified | COMPLETED | Feasibility of the Oricol™ Sampling Device to Retrieve Vagina Mucus (Wall) Samples for Genomic & Epigenetic Analysis. |
| NCT05817292 | Not specified | COMPLETED | Study of the Vaginal Microbiota in Women Under Fertile Age |
| NCT05872178 | Not specified | COMPLETED | Omegia Softgel Clinical Research Program |
| NCT05888116 | Not specified | COMPLETED | Efficacy and Safety of a Hyaluronic Acid-Based Vaginal Moisturizer Medical Device to Ease Symptoms of Vaginal Dryness |
| NCT06470906 | Not specified | COMPLETED | Feasibility of an Oral Intervention for Sexual Health in Transgender Men |
| NCT06519799 | Not specified | UNKNOWN | Integrated Genetic and Functional Analysis of the Influence of Menstrual Hygiene Products on Female Health |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| OSPEMIFENE | 4 | 4 |
| DEQUALINIUM | 4 | 3 |
| DESFLURANE | 4 | 1 |
| SEVOFLURANE | 4 | 1 |
| YEAST, DRIED | -1 | 1 |
Related Atlas pages
- Drugs: Ospemifene, Dequalinium, Desflurane, Sevoflurane